Local gastric and serum concentrations of rebamipide following oral administration to patients with chronic gastritis.
The potential anti-ulcer action of rebamipide (CAS 11911-87-6, OPC-12759) on experimental and clinical injury to the gastric mucosa depends on its presence in sufficient concentration in the gastric mucosa. To investigate its local penetration, rebamipide levels in the gastric mucosa and serum were measured. A dose of 100 mg of rebamipide was given orally (tablet) to patients with chronic gastritis (n = 32). Gastroscopy was performed between 22 and 353 min after drug ingestion. Venous blood was sampled for determination of serum concentrations. Samples were analyzed by high-performance liquid chromatography (HPLC). The maximal concentration in the gastric mucosa was reached after 30-60 min, and the concentration remained elevated for about 120 min thereafter. The mean mucosal concentration of rebamipide between 30 and 120 min after ingestion was 60.0 +/- 109.8 micrograms/g of tissue, which was higher than 0.1 mmol/l (37 micrograms/g of tissue). The serum concentration of rebamipide peaked about 30-60 min after drug ingestion and remained elevated for about 5 h thereafter. The mean serum concentration of rebamipide between 30 and 120 min after ingestion was 0.25 +/- 0.23 microgram/ml, being below the level of 1.0 mumol/l (0.37 microgram/ml). Data indicate that the concentration of rebamipide in the gastric mucosa resulted from local penetration, and suggest that the blood level and systemic distribution of rebamipide have little effect on its antioxidative and anti-neutrophilic activities.
Naito
Y
Y
First Department of Medicine, Kyoto Prefectural University of Medicine, Japan.
Yoshikawa
T
T
Iinuma
S
S
Miyazaki
R
R
Yagi
N
N
Yoshida
N
N
Osumi
T
T
Hirao
Y
Y
Kondo
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000409:Alanine / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D000897:Anti-Ulcer Agents / Q000097:blood / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D002908:Chronic Disease; D005260:Female; D005753:Gastric Mucosa / Q000378:metabolism*; D005756:Gastritis / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015363:Quinolones / Q000097:blood / Q000493:pharmacokinetics*
D000897:Anti-Ulcer Agents; D015363:Quinolones; C052785:rebamipide; D000409:Alanine